Lentiginous eruption due to topical immunotherapy [6]

Archives of Dermatology

Volumn 139, Issue 4, 2003, Pages 544-545

  Tosti, Antonella ^a   Piraccini, Bianca Maria ^b   Misciali, Cosimo ^b   Vincenzi, Colombina ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; SQUARIC ACID DIBUTYL ESTER;

ADOLESCENT; ALOPECIA; CASE REPORT; CELL ULTRASTRUCTURE; CLINICAL FEATURE; DERMOEPIDERMAL JUNCTION; DRUG EFFECT; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; LENTIGO; LETTER; MALE; MELANOCYTE; PRIORITY JOURNAL; RELAPSE; SKIN BIOPSY; SYMPTOM;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ALOPECIA AREATA; CYCLOBUTANES; DRUG ERUPTIONS; HUMANS; LENTIGO; MALE; MELANOCYTES;

EID: 0037388494     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.4.544     Document Type: Letter

References (5)

1. Buckley DA, Du Vivier AWP. The therapeutic use of topical contact sensitisers in benign dermatoses. Br J Dermatol. 2001;145:385-405.
2. Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model immunotherapy of alopecia areata with diphencyprone. Arch Dermatol. 2001;137:1063-1068.
3. Papa CM, Kligman AM. The behavior of melanocytes in inflammation. J Invest Dermatol. 1965;45:465-474.
4. Imokawa G, Kawai M, Mishima Y, Motegi I. Differential analysis of experimental hypermelanosis induced by UVB, PUVA and allergic contact dermatitis using a brownish guinea pig model. Arch Dermatol Res. 1986;278:352-362.
5. Lever IR, Farr PM. Skin cancer or premalignant lesions occur in half of highdose PUVA patients. Br J Dermatol. 1994;131:215-219.